Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Cost-Utility Analysis Comparing Radioactive Iodine, Anti-Thyroid Drugs and Total Thyroidectomy for Primary Treatment of Graves’ Disease
source: European Journal of Endocrinology / European Federation of Endocrine Societies
year: 2016
authors: Donovan PJ, McLeod DS, Little R, Gordon L
summary/abstract:Objective:
Little data is in existence about the most cost-effective primary treatment for Graves’ disease. We performed a cost-utility analysis comparing radioactive iodine (RAI), anti-thyroid drugs (ATD) and total thyroidectomy (TT) as first-line therapy for Graves’ disease in England and Australia.
Methods:
We used a Markov model to compare lifetime costs and benefits (quality-adjusted life-years (QALYs)). The model included efficacy, rates of relapse and major complications associated with each treatment, and alternative second-line therapies. Model parameters were obtained from published literature. One-way sensitivity analyses were conducted. Costs were presented in 2015£ or Australian Dollars (AUD).
Results:
RAI was the least expensive therapy in both England (£5425; QALYs 34.73) and Australia (AUD5601; 30.97 QALYs). In base case results, in both countries, ATD was a cost-effective alternative to RAI (£16 866; 35.17 QALYs; incremental cost-effectiveness ratio (ICER) £26 279 per QALY gained England; AUD8924; 31.37 QALYs; ICER AUD9687 per QALY gained Australia), while RAI dominated TT (£7115; QALYs 33.93 England; AUD15 668; 30.25 QALYs Australia). In sensitivity analysis, base case results were stable to changes in most cost, transition probabilities and health-relative quality-of-life (HRQoL) weights; however, in England, the results were sensitive to changes in the HRQoL weights of hypothyroidism and euthyroidism on ATD.
Conclusions:
In this analysis, RAI is the least expensive choice for first-line treatment strategy for Graves’ disease. In England and Australia, ATD is likely to be a cost-effective alternative, while TT is unlikely to be cost-effective. Further research into HRQoL in Graves’ disease could improve the quality of future studies.
DOI: 10.1530/EJE-16-0527
read more full text
myBinderRelated Content
-
...Hyperthyroidism is caused when the thyro...
-
Thyroglobulin Autoantibodies are Associated With Refractoriness to Antithyroid Drug Treatment for Graves’ Dise...Objective: The recurrence rate associat...
-
Advances in Treatment of Active, Moderate-To-Severe Graves’ OphthalmopathyGraves' ophthalmopathy is defined as aut...
-
Radioactive Iodine Can Be First-Line for Hyperthyroidism, Says UKNew UK guidelines for the treatment of h...
-
Gender Influences the Clinical Presentation and Long-Term Outcome of Graves’ DiseaseObjective: The outcome of antithyroid d...
-
Quality of Life, Clinical Outcomes and Safety of Early Prophylactic Levothyroxine Administration in Patients With Gr...Objective: While radioiodine therapy is...
-
Successful Re-Administration of Low-Dose of Methimazole (MMI) in Graves’ Disease Patients who Experienced Alle...Objective: When patients with Graves' d...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google